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Drug coverage in Canada varies widely despite uni-versal coverage for physician and hospital services.1 Some provinces, including British Columbia, Sas-
katchewan, Manitoba, and Newfoundland and Labrador, 
provide coverage through so-called income-based coverage 
programs. These programs require households to spend a 
fixed proportion of their household income on prescription 
drugs before public coverage takes effect. Other provinces 
have coverage programs that include deductibles for particu-
lar segments of the population, such as Ontario’s Trillium 
Program for residents aged 25–64 years.
We know from prior surveys that cost-related nonadher-
ence remains an issue for many Canadians.2 Furthermore, the 
use of deductibles is potentially problematic, as there is exten-
sive evidence, from both Canada and other countries, that 
out-of-pocket copayments reduce the use of essential drugs.3–5 
However, the specific impact of income-based deductibles 
remains less clear. For example, an analysis done shortly after 
BC’s income-based plan Fair PharmaCare was implemented, 
in 2003, suggested the plan did not alter population-level pre-
scription drug use,6 whereas, evidence from Manitoba sug-
gested that income-based deductibles decreased the use of 
inhaled corticosteroids by children with asthma.7 Yet as with 
the BC study, the prior coverage regimen in Manitoba 
included a deductible per family.7 Our recent study using a 
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Background: Several Canadian public drug plans have income-based deductibles, but we have limited data on their impact, particu-
larly for vulnerable populations. Therefore, we studied the impact of deductibles in British Columbia’s Fair PharmaCare program on 
drug use among lower-income adults.
Methods: We used a quasi-experimental regression discontinuity design to study the impact of BC rules that impose no deductible 
before receiving public coverage on households with incomes less than $15 000, a deductible of 2% of household income on those 
with incomes between $15 000 and $30 000, and a deductible of 3% of household income on those with incomes above $30 000. 
We studied the impact of these thresholds on public and total drug expenditures between 2003 and 2015 using 24 million person-
years of data.
Results: Both thresholds decreased the proportion of beneficiaries receiving benefits, by 0.33 (95% confidence interval [CI] –0.34 to 
–0.30) and 0.05 (95% CI –0.064 to –0.032) respectively. There were also substantial reductions in the extent of public drug plan 
expenditures ($59.94 [95% CI –74.74 to –45.14] and $26.12 [95% CI –39.78 to –12.46], respectively). The change at the $15 000 
threshold reduced patient drug expenditures by $26.00 (95% CI –45.48 to –6.51), or 7.2%. In contrast, we found no statistically sig-
nificant change in total expenditures when households moved from a deductible of 2% to 3% at the $30 000 threshold.
Interpretation: Income-based deductibles considerably affected the extent of public subsidy for prescription drugs. For lower-income 
households making around $15 000, the deductible led to a reduction of 7.2% in overall drug use and costs. Although deductibles are 
a useful tool to limit public expenditures, policy-makers should be cautious in their use among vulnerable populations.
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regression discontinuity design showed that income-based 
deductibles did not affect overall use of drugs or health care 
services.8 That study, however, focused on older adults, and, 
therefore, the results may not be generalizable to other seg-
ments of the population.
The implications of the existing evidence on the impact of 
income-based deductibles on drug use for specific populations 
in Canada are unclear. Prior work in the United States 
showed that deductibles can reduce expenditures, but it is 
unclear for whom.9 This uncertainty has led to a major debate 
on the role that income-based deductibles should play in 
Canadian drug plans. For example, although a report from the 
Institute for Research on Public Policy indicated that Fair 
PharmaCare should not be emulated in other provinces,10 
other bodies such as the C.D. Howe Institute have recom-
mended it as a model policy for reforming Ontario’s public 
drug plan.11 One important aspect of this debate is the degree 
to which government can offset expenditures while minimiz-
ing the impact on patients. To help inform this debate, we 
studied the impact of 2  thresholds in BC’s Fair PharmaCare 
using a strong observational study design with a particular 
focus on lower-income adults.
Methods
Context
British Columbia offers residents public drug coverage 
through the Fair PharmaCare program, which provides drug 
coverage to all residents with a deductible that is based on 
household income. The plan covers a comprehensive list of 
prescription drugs. Fair PharmaCare deductibles are deter-
mined based on net household income, verified by the Canada 
Revenue Agency, from 2 years prior. The program operates 
alongside universal hospital and physician coverage for medi-
cally necessary services that does not use patient copayments.
Our study leveraged “breaks” in coverage created by 
2  changes in the deductible structure of Fair PharmaCare. 
One such break occurs at $15 000, where households move 
from having no deductible to having a deductible equivalent 
to 2% of household income. A second break, at $30 000, 
requires households to spend 3% of net household income 
before receiving public coverage. Beyond these thresholds, 
households must pay 30% of the cost of prescription drugs up 
to a household maximum of 3% and 4%, respectively. These 
2  thresholds introduce substantial discontinuities into the 
out-of-pocket obligations for households just below and just 
above these 2  income levels (Appendix 1, available at www.
cmajopen.ca/content/7/1/E167/suppl/DC1). For instance, a 
household with a total income of $14 999 would have no 
deductible and pay a maximum of $300 per year, whereas one 
with an income of $15 000 would have a $300 deductible and 
pay a maximum of $450.
Data sources
We obtained data from the BC PharmaNet system, a 
population-based administrative data system on drug dispen-
sations in BC between 2003 and 2015. As all community 
pharmacies are required to submit claims through this system, 
the database is highly accurate and complete, capturing all 
drug dispensations in the community setting in real time. 
Using PharmaNet, we captured data on individual prescrip-
tions, including drug information, total cost and the publicly 
paid portion.
Population
Our study focused on a population-based open cohort of peo-
ple eligible for BC Fair PharmaCare coverage during the 
study period. We included only those who registered for Fair 
PharmaCare, as household income data were not available for 
nonregistered households. In fiscal 2016/17, 1 253 497  fami-
lies, representing about two-thirds of BC’s 1 881 970 house-
holds,12 were registered for Fair Pharmacare.13 People who 
received drug benefits through the federal government were 
also excluded as they would not have been subject to the same 
program rules.
This analysis included all enrollees who were consistently 
eligible for the standard Fair PharmaCare benefit (known as 
Plan I) in each calendar year and for whom verified income 
information was available. Given the structure of Fair 
PharmaCare, this would include only people born after 1939, 
as those born in 1939 or earlier would have been eligible for 
so-called enhanced assistance, which had lower deductibles. 
Plan I is the largest of BC’s pharmacare programs and is 
open to all BC residents. Other pharmacare programs are 
available for people receiving social assistance, those with 
particular illnesses and those in residential care facilities.13 
Importantly for this analysis, Plan I is the only program that 
includes the described deductibles. We focused our analysis 
on households with incomes of $61 667 or less. We chose 
this threshold as it represented the top end of the income 
bracket that was double the $30 000 threshold. We defined 
this a priori and assumed it would give us enough points to fit 
a smooth line without being unduly influenced by higher 
income levels. As we could obtain only 1 of the 25 different 
Fair PharmaCare income bands for each person, we assigned 
each person the midpoint income within each Fair Pharma-
Care plan code for all analyses (e.g.,  we used $22 500 for 
Plan Code IB, which includes households with incomes 
between $21 250 and $23 750).
The unit of analysis was the person-year. We excluded any 
residents who had claims under any other Fair PharmaCare 
plan (B, C, D, F, G or P) during the year(s) in question to 
limit potential contamination from other plans that do not 
impose the same deductible structure. We also excluded 
person-years in which the person changed income bands dur-
ing the year in question.
Outcome measures
We studied the impact of income-based deductibles on out-
comes within 2 broad categories:
• System-level outcomes: We calculated the proportion of 
enrollees in each income band per person-year to estimate 
the impact of deductibles on the proportion receiving any 
public drug plan benefits. Second, we calculated the 
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average amount paid by the public Fair PharmaCare pro-
gram per person-year to estimate the impact of deductibles 
on the extent of public plan spending.
• Patient-level outcomes: We calculated the average total 
prescription drug expenditure (including both public and 
private portions), the average number of prescriptions dis-
pensed and the number of unique medicines (based on 
Anatomical Therapeutic Chemical Classification System 
level 7 codes) per person-year in our cohort.
Statistical analysis
We used a regression discontinuity analysis, one of the stron-
gest quasi-experimental research designs, to study the impact 
of deductibles on our outcomes.14,15 This method leverages 
the quasi-random nature of the change in program design at 
the $15 000 and $30 000 household income thresholds to 
derive causal estimates of real-world impacts.16 As people on 
either side of these thresholds are likely similar on other char-
acteristics, any abrupt differences in their drug use may be 
attributed to the effects of the plan design. The major 
assumption in such an analysis is that all potential confound-
ers do not have abrupt changes across this threshold. Regres-
sion discontinuity designs have a long history in economics, 
and their use is increasing within the medical literature.17,18
To fit our statistical models, we first determined the aver-
age for each outcome across all person-years in our data set 
within each income band. As the use of deductibles varied 
based on household income, this was the forcing variable in 
our models. Using these aggregate figures, we fit linear 
regression models that included breaks at both thresholds, as 
well as linear and quadratic trend parameters within each 
group:
Outcome = β0 + β1 · Xi + β2 · X2i + β3 [Xi > 15 000] + β4 (Xi – 
15 000) · [Xi > 15 000] + β5 (Xi – 15 000) · [Xi > 15 000]2 + β6 [Xi > 
30 000] + β7 (Xi – 30 000) · β8 (Xi – 30 000) · [Xi > 30 000]2 + εi
where X represents the forcing variable of household income, 
and 15 000 and 30 000 represent the 2  cut-off points. The 
parameters of interest from the regression results are β3, 
which represents the change in the outcome at the $15 000 
income threshold, and β6, which represents the change in the 
outcome at the $30 000 threshold.
Ethics approval
The study was approved by the University of British Colum-
bia Behavioural Research Ethics Board.
Results
Cohort characteristics
After we excluded 11 420 158 person-years with income greater 
than $61 666, our final cohort consisted of 12 706 804 person-
years contributed by 2 178 162 unique individuals. The cohort 
had slightly more females than males (51.6% v. 48.4%), and the 
average age of people in their first year in the cohort was 
38.1 years. The mean number of prescriptions dispensed per 
year was 6.7 (Table 1).
System-level outcomes
Analysis of the proportion of enrollees receiving Fair Pharma-
Care benefit payments showed that the move from no deduct-
ible to a deductible of 2% of household income led to an 
absolute decrease of 33% (95% CI –0.34 to –0.30) in the pro-
portion of enrollees receiving public benefits, from 54% to 
21% (Figure 1). This represents a relative decrease of 61%. 
We found a smaller reduction (5%, 95% CI –0.064 to –0.032) 
in the proportion receiving benefits at the $30 000 threshold, 
from 18% to 13% .
Consistent with this decrease in the proportion receiving 
benefits, we found substantial decreases in the extent of public 
drug plan expenditures across the 2 income thresholds. There 
was a reduction of $59.94 (95% CI –74.74 to –45.14) in the 
mean annual Fair PharmaCare reimbursement at the $15 000 
threshold, representing a relative decrease of 27%, and a 
decrease of $26.12 (95% CI –39.78 to –12.46) at the $30 000 
threshold (Figure 2).




person-years % of cohort
Total no. of person-years 24 126 962 100.0
Sex
    Female 12 457 638 51.6
    Male 11 668 294 48.4
    Unknown/unspecified 1030 < 0.1
Age, yr
    < 18 4 880 854 20.2
    18–29 3 766 248 15.6
    30–44 4 809 124 19.9
    45–64 8 840 679 36.6
    ≥ 65 1 830 057 7.6
No. of prescriptions annually
    0 8 200 161 34.0
    1–3 6 517 766 27.0
    4–6 3 050 005 12.6
    7–9 1 729 357 7.2
    ≥ 10 4 629 673 19.2
Household size, no. of people
    1 4 758 066 19.7
    2 5 760 859 23.9
    3 3 104 824 12.9
    ≥ 4 10 503 213 43.5
Income band, $
    < 15 000 2 780 122 11.5
    15 000–30 000 3 346 896 13.9
    > 30 000 17 999 944 74.6




In comparison to the large difference in public subsidies, we 
found smaller changes in patient drug use and costs at the 
2  income thresholds. There was a reduction of $26.00 (95% 
CI –45.48 to –6.51) in annual total drug expenditures at the 
$15 000 threshold (Figure 3). This represented an absolute 


























No deductible 2% deductible 3% deductible
Figure 1: Regression discontinuity analysis across income thresholds of mean proportion of beneficiaries with a claim where 
Fair PharmaCare paid a portion.
























No deductible 2% deductible 3% deductible
Figure 2: Regression discontinuity analysis of mean annual drug expenditures by the Fair PharmaCare program across 
income thresholds.
OPEN
 CMAJ OPEN, 7(1) E171
Research
decrease of 7.2% in total expenditures when households 
moved across the threshold from no public drug plan deduct-
ible to a deductible of 2% of household income. In contrast, 
we found no statistically significant change in total expendi-
tures when households moved from deductibles of 2% to 3% 
of household income at the $30 000 threshold (estimate 
$6.10, 95% CI –24.08 to 11.89).
Analysis of total prescriptions showed only small reductions 
in the average number of individual prescriptions received. We 
found nonsignificant reductions of 0.35 prescriptions (95% CI 
–0.79 to 0.09) at the $15 000 threshold and 0.14 prescriptions 
(95% CI –0.54 to 0.267) at the $30 000 threshold (Figure 4). 
We also found a small decrease in the number of unique medi-
cines received: the average annual number of unique drugs 
filled above and below the $15 000 thresholds was reduced by 
0.07 drugs (95% CI –0.12 to –0.03) per beneficiary, an abso-
lute decrease of 4.8% (Figure 5). We found no significant 
change in the number of unique medicines received at the 
$30 000 threshold (estimate 0.00, 95% CI –0.04 to 0.04).
Interpretation
In this quasi-experimental study of the impact of household-
level deductibles on drug use, we found that, for lower-income 
households with incomes around $15 000, deductibles led to a 
notable reduction in the proportion of beneficiaries who receive 
any public subsidy, as well as in overall drug use and costs. In 
contrast, once at an income of $30 000, a move from a deduct-
ible of 2% of household income to 3% of household income 
appeared to have no notable impact on these same outcomes.
Our results suggest that the impact of deductibles differs 
between different populations in BC. In contrast, our prior 
study examining a very similar change from no deductible to a 
deductible of 2% of household income for those born in 1939 
or earlier and after 1939 showed no change in overall drug 
use.8 Although the population in that study had incomes just 
above the threshold in the present study ($15 000–$30 000), 
we believe that the major difference is the age of the popula-
tions under study — an average age of 66 years in the prior 
study versus 38 years in the present study. This is consistent 
with differences in cost-related nonadherence reported in a 
survey study, in which younger populations consistently 
reported more issues in affording their prescription drugs 
than did older populations.19 Our lack of an impact of the 
change from a deductible of 2% of household income to 3% 
of household income at $30 000 suggests that, beyond a cer-
tain income level, marginal changes in the deductible may not 
be major determinants of drug access.
Limitations
As with any analysis of administrative claims data, our study 
has several limitations worth noting. First, we did not have 
data on the clinical indication for the prescriptions that were 
written, nor did we have information on the characteristics of 
prescriptions that were foregone by people at different 
income levels. Furthermore, we lacked data on the presence 
or lack of private drug insurance held by the person in ques-
tion or another person such as a spouse. This is a major miss-
ing factor in our analysis, particularly as private insurance 
would insulate them from paying the Fair PharmaCare 





















No deductible 2% deductible 3% deductible
Figure 3: Regression discontinuity analysis of average total prescription drug expenditure above and below the income 
thresholds.
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deductibles. It is important to note, however, that private 
insurance does cover 60% of Canadians,20 and, thus, we feel 
that our results represent the true impact of income-based 
deductibles in Canada. In addition, we feel that the presence 
of employer-based coverage would likely not have biased our 
results, as there is no reason to believe that there is an abrupt 
30 000
Household income, $

















No deductible 2% deductible 3% deductible
Figure 4: Regression discontinuity analysis of average annual number of prescriptions filled above and below the income 
thresholds.



















No deductible 2% deductible 3% deductible
Household income, $
Figure 5: Regression discontinuity analysis of average annual number of unique drugs (Anatomical Therapeutic Chemical 
Classification System level 7) filled above and below the income thresholds.
OPEN
 CMAJ OPEN, 7(1) E173
Research
change in private coverage at a household income of $15 000 
or $30 000. This also precluded our ability to examine 
changes in out-of-pocket payments across the income thresh-
olds. Our analysis was restricted to those who were registered 
for Fair PharmaCare. Although it is unknown whether there 
are sociodemographic differences between those who register 
and those who do not, lower-income people without private 
insurance are more likely than those with higher incomes to 
rely on public drug programs. Thus, this restriction is 
unlikely to have biased our significant result at the $15 000 
threshold. Finally, we were unable to assess the impact of 
deductibles on patient outcomes or the use of other health 
care services.
Conclusion
Our results suggest that public drug coverage programs 
should be cognizant of how using income-based deductibles 
may affect the members of their plans. In particular, our 
results show that the current use of deductibles is offsetting 
significant public expenditure in BC. Furthermore, this is hav-
ing an impact on prescription drug use for households with 
low incomes, reducing it by an estimated 7.2%, but an 
increase in the deductible at a higher income level did not 
have a similar impact. Moves in the US to cover first-line 
medicines for chronic conditions — so-called value-based 
insurance designs — might provide a model for how to 
exempt certain classes from deductibles to avoid this type of 
impact.21,22 Moreover, it will be important to assess the impact 
of changes to the deductible structure by the BC government 
that will increase the threshold for the imposition of deduct-
ibles to $30 000 on Jan. 1, 2019.
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